Market
Will Ionis' Tryngolza reach $50 million in U.S. sales by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Ionis Pharmaceuticals' official financial reports and press releases
Story
Ionis Pharmaceuticals Secures FDA Approval for Tryngolza, Its First Wholly-Owned Drug for Familial Chylomicronemia Syndrome, Lowers Triglycerides
Dec 19, 2024, 10:25 PM
Ionis Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug Tryngolza, designed to treat familial chylomicronemia syndrome, a rare genetic disorder that affects the body's ability to break down fats. This approval marks a significant milestone for Ionis, as it is the company's first wholly-owned drug. The therapy works by lowering triglyceride levels in patients suffering from this condition, which can lead to severe health complications. The FDA's decision was confirmed through various sources, highlighting the importance of this approval for both the company and patients in need of effective treatment options.
View original story
Similar markets
Increase by more than 20% • 25%
No significant increase • 25%
Increase between 10% and 20% • 25%
Increase by less than 10% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $500 million • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
$500 million to $1 billion • 25%
More than $200 million • 25%
$100 million to $200 million • 25%
$50 million to $100 million • 25%
Less than $50 million • 25%